Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
|
|
Hyperfine, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"HYPERFINE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2023 December 31, 2022 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 93,948 $ 117,472 Restricted cash 969 771 Accounts receivable, less allowance of $175 and $180 as of June 30, 2023 and December 31, 2022, respectively 3,948 2,103 Unbilled receivables 663 454 Inventory 5,983 4,622 Prepaid expenses and other current assets 2,312 3,194 Due from related parties — 48 Total current assets 107,823 128,664 Property and equipment, net 3,058 3,248 Other long term assets 1,725 2,139 Total assets $ 112,606 $ 134,051 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 1,372 $ 678 Deferred grant funding 969 771 Deferred revenue 1,490 1,378 Due to related parties 45 — Accrued expenses and other..." |
|
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"HYPERFINE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2023 December 31, 2022 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 104,027 $ 117,472 Restricted cash 713 771 Accounts receivable, less allowance of $191 and $180 as of March 31, 2023 and December 31, 2022, respectively 3,018 2,103 Unbilled receivables 713 454 Inventory 5,744 4,622 Prepaid expenses and other current assets 2,923 3,194 Due from related parties — 48 Total current assets 117,138 128,664 Property and equipment, net 3,091 3,248 Other long term assets 1,873 2,139 Total assets $ 122,102 $ 134,051 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 1,668 $ 678 Deferred grant funding 713 771 Deferred revenue 1,415 1,378 Due to related parties 64 — Accrued expenses and ot..." |
|
| 03/21/2023 |
8-K
| Quarterly results|
Docs:
|
"HYPERFINE, INC. AND SUBSIDIARIES COMBINED AND CONSOLIDATED BALANCE SHEETS December 31, December 31, 2022 2021 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 117,472 $ 188,498 Restricted cash 771 2,662 Accounts receivable, net 2,103 553 Unbilled receivables 454 91 Inventory 4,622 4,310 Prepaid expenses and other current assets 3,194 1,357 Due from related parties 48 14 Total current assets $ 128,664 $ 197,485 Property and equipment, net 3,248 3,753 Other long term assets 2,139 1,235 Total assets $ 134,051 $ 202,473 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 678 $ 2,248 Deferred grant funding 771 2,662 Deferred revenue 1,378 730 Due to related parties — 1,981 Accrued expenses and other current liabilities 5,976 8,115 Total current liabilities $ 8,803 $ ..." |
|
| 08/10/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/23/2022 |
8-K
| Quarterly results|
Docs:
|
"HYPERFINE, INC. AND SUBSIDIARIES COMBINED AND CONSOLIDATED BALANCE SHEETS December 31, 2021 2020 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 188,498 $ 62,676 Restricted cash 2,662 1,610 Accounts receivable, net 553 174 Unbilled receivables 91 — Inventory 4,310 1,718 Prepaid expenses and other current assets 1,357 691 Due from related parties 14 1,465 Total current assets $ 197,485 $ 68,334 Property and equipment, net 3,753 1,904 Other assets - related party — 1,244 Other long term assets 1,235 44 Total assets $ 202,473 $ 71,526 LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 2,248 $ 948 Deferred grant funding 2,662 1,610 Deferred revenue 730 158 Due to related parties 1,981 136 Accrued expenses and other current liabilities ...",
"MRI 1.0 1980 MRI 2.0 1990 MRI 3.0 FDA" |
|
|
|